Fig. 3
From: Implications of cardiac markers in risk-stratification and management for COVID-19 patients
Severe/critical COVID-19 patients with evidence of abnormal cardiac markers have poor clinical outcomes. a Number of patients with abnormal and normal levels of BNP, hs-TNI, α-HBDH, CK-MB, and LDH during hospitalization. The mortality (b) and ICU admission rate (c) of severe/critical COVID-19 patients with abnormal serum levels of BNP, hs-TNI, α-HBDH, CK-MB, and LDH during hospitalization. d Number of patients with abnormal and normal levels of BNP, hs-TNI, α-HBDH, CK-MB, and LDH within the first week after admission. The mortality (e) and ICU admission rate (f) of severe/critical COVID-19 patients with abnormal serum levels of BNP, hs-TNI, α-HBDH, CK-MB, and LDH within the first week after admission. g Serum levels of BNP, hs-TNI, α-HBDH, CK-MB, and LDH during hospitalization for non-survivors and survivors. Shaded regions represent a 95% confidence interval